Research programme: anti-tropomyosin therapeutics - Novogen

Drug Profile

Research programme: anti-tropomyosin therapeutics - Novogen

Alternative Names: Anisina; Anti-tropomyosins - Novogen; ATM drugs - Novogen; ATM-3507; Tm5NM1 protein inhibitors - Novogen; Tpm3.1 protein inhibitors - Novogen; TR 100

Latest Information Update: 16 Jun 2016

Price : $50

At a glance

  • Originator Genscreen; University of New South Wales
  • Developer Nationwide Children's Hospital; Novogen
  • Class Small molecules
  • Mechanism of Action Tropomyosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma; Neuroblastoma; Prostate cancer
  • Research Ovarian cancer

Most Recent Events

  • 14 Jun 2016 Novogen has patent protection for ATM-based drugs including anisina (ATM 3507) in Australia
  • 19 Feb 2016 Novogen's patent application covering next-generation ATM-based drugs has been examined and accepted by the Australian Patent Office
  • 10 Nov 2015 Preclinical data in Neuroblastoma released by Novogen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top